Start of patient recruitment for MITIGATE clinical study

MITIGATE is recruiting patients with metastatic GIST who are experiencing tumour progression while under treatment with Imatinib (Glivec®, Gleevec™) for a diagnostic clinical study.

MITIGATE uses an innovative imaging approach focusing on progressive tumour lesions. While the approach is diagnostic rather than therapeutic, patients may derive real benefits from the new imaging procedure, such as improved tumour volume definition and better detection of disease.

European patients with metastatic GIST can fill out the enrolment questionnaire to determine whether you meet the requirements for participation in our study. You access the questionnaire by clicking here.